Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.58 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655408 | 0.92 | PLA2G10 (0.48) | PLA2G10ECE1THRBMAOBNOTUM | |
| SCHEMBL4656120 | 0.90 | ECE1 (0.50) | PLA2G10ECE1MAOBNOTUMRORC | |
| SCHEMBL4656220 | 0.87 | ECE1 (0.59) | ECE1MAOBNOTUMMEN1TP53 | |
| SCHEMBL4656242 | 0.86 | ECE1 (0.49) | ECE1THRBMAOBNOTUMMEN1 | |
| SCHEMBL4655289 | 0.83 | ECE1 (0.53) | ECE1MAOBNOTUMMEN1TP53 | |
| SCHEMBL4656319 | 0.83 | ECE1 (0.50) | ECE1MAOBNOTUMMEN1TP53 | |
| SCHEMBL28788204 | 0.83 | ECE1 (0.48) | PLA2G10ECE1MAOBNOTUMMEN1 | |
| SCHEMBL3574151 | 0.82 | PPARG (0.64) | ECE1PPARG | |
| SCHEMBL4655241 | 0.82 | NOTUM (0.49) | ECE1MAOBNOTUMMEN1TP53 | |
| SCHEMBL3158425 | 0.82 | PLA2G10 (0.57) | PLA2G10ECE1MAOBKDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101010297-B | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2011-07-27 | — | — | CN | claimed |
| EP-1776340-B1 | N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2008-12-03 | — | — | EP | claimed |
| CN-101010297-B | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS | 2011-07-27 | — | — | CN | disclosed |
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| EP-1776340-B1 | N-(1H-INDOLYL)-H-INDOLE-2-CARB0XAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| CN-101010297-A | N- (1H-indolyl) -1H-indole-2-carboxamide derivatives, their preparation and their pharmaceutical use | SANOFI AVENTIS (FR) | 2007-08-01 | — | — | CN | disclosed |
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | IDO1, IDO2, NPY5R | PLA2G10 3074/4885ECE1 1424/4885THRB 1537/4885 |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885ECE1 1609/4885THRB 1429/4885 |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | NPY5R, TPH2, TPH1 | PLA2G10 3198/4885ECE1 1609/4885THRB 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.